TY  - GEN
AU  - Robak,Tadeusz
AU  - Jin,Jie
AU  - Pylypenko,Halyna
AU  - Verhoef,Gregor
AU  - Siritanaratkul,Noppadol
AU  - Drach,Johannes
AU  - Raderer,Markus
AU  - Mayer,Jiri
AU  - Pereira,Juliana
AU  - Tumyan,Gayane
AU  - Okamoto,Rumiko
AU  - Nakahara,Susumu
AU  - Hu,Peter
AU  - Appiani,Carlos
AU  - Nemat,Sepideh
AU  - Cavalli,Franco
TI  - Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
SN  - 1474-5488
PY  - 2019///0610
KW  - Aged
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Asia
KW  - Bortezomib
KW  - Cyclophosphamide
KW  - Disease Progression
KW  - Doxorubicin
KW  - Europe
KW  - Female
KW  - Humans
KW  - Lymphoma, Mantle-Cell
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - North America
KW  - Prednisone
KW  - Progression-Free Survival
KW  - Rituximab
KW  - Time Factors
KW  - Vincristine
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(18)30685-5
ER  -